Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.
An opinionated take on NEJM highlights for the second quarter of 2023
By
Marc Herant
NEJM
Read more
Trends and strategy in oncology development
By
Marc Herant
Biopharma
Read more
An opinionated take on NEJM highlights for the first quarter of 2023
By
Marc Herant
NEJM
Read more
An opinionated take on NEJM highlights for December 2022
By
Marc Herant
NEJM
Read more
Hearts and souls: An opinionated take on NEJM highlights for October and November 2022
By
Marc Herant
NEJM
Read more
Some very disappointing failures: An opinionated take on NEJM highlights for August and September 2022
By
Marc Herant
NEJM
Read more
Trends in oncolytic virus therapeutics: then and now
By
Marc Herant
Biopharma
Read more
An excellent July vintage: an opinionated take on NEJM highlights for July 2022
By
Marc Herant
NEJM
Read more
An opinionated take on NEJM highlights for June 2022
By
Marc Herant
NEJM
Read more
An opinionated take on NEJM highlights for May 2022
By
Marc Herant
NEJM
Read more
An opinionated take on NEJM highlights for March-April 2022
By
Marc Herant
NEJM
Read more
The growth of small molecule drug classes over time
By
Marc Herant
Biopharma
Read more
An opinionated take on NEJM highlights for January-February 2021
By
Marc Herant
NEJM
Read more
Wrapping up 2021: An opinionated take on NEJM highlights for November-December 2021
By
Marc Herant
NEJM
Read more
Taking on tough indications: An opinionated take on NEJM highlights for October 2021
By
Marc Herant
NEJM
Read more
From bleeding edge to basics: an opinionated take on NEJM highlights for August and September 2021
By
Marc Herant
NEJM
Read more
JAMA Network: Trends in the Concentration and Distribution of Health Care Expenditures in the US, 2001-2018
By
Marc Herant
In the News
Read more
Summer catch-up: an opinionated take on NEJM highlights for May-July 2021
By
Marc Herant
NEJM
Read more
Clinicaltrials.gov and AI-related studies: a brief status check in April 2021
By
Marc Herant
Digital
,
Read more
Remodel, rewire, repopulate: an opinionated take on NEJM highlights for April 2021
